Research Topics
| Jeffrey S BrownSummaryAffiliation: Harvard Medical School and Harvard Pilgrim Health Care Country: USA Publications
| Collaborators
|
Detail Information
Publications
Active influenza vaccine safety surveillance: potential within a healthcare claims environmentJeffrey S Brown
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
Med Care 47:1251-7. 2009..Rapid safety assessment of novel vaccines, especially those targeted against pandemic influenza, is a public health priority...- Distributed health data networks: a practical and preferred approach to multi-institutional evaluations of comparative effectiveness, safety, and quality of careJeffrey S Brown
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA 02215, USA
Med Care 48:S45-51. 2010.... 
Early detection of adverse drug events within population-based health networks: application of sequential testing methodsJeffrey S Brown
Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA
Pharmacoepidemiol Drug Saf 16:1275-84. 2007....- Early adverse drug event signal detection within population-based health networks using sequential methods: key methodologic considerationsJeffrey S Brown
Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
Pharmacoepidemiol Drug Saf 18:226-34. 2009..Our objective was to expand our previous signal detection work by investigating the effect on signal detection of alternative study specifications... - Outpatient urticaria diagnosis codes have limited predictive value for same-day influenza vaccine adverse event detectionKristen M Moore
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA
J Clin Epidemiol 63:407-11. 2010..To assess the predictive value of claims-based outpatient urticaria diagnosis codes to identify potential vaccine-related adverse events (AEs) when recorded on the same day as influenza vaccination... - Drug safety data mining with a tree-based scan statisticMartin Kulldorff
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA The HMO Research Network Center for Education and Research in Therapeutics
Pharmacoepidemiol Drug Saf 22:517-23. 2013..This methodological paper evaluates the tree-based scan statistic data mining method to enhance drug safety surveillance... - A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine StudyPriscilla Velentgas
Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
Pharmacoepidemiol Drug Saf 17:1226-34. 2008..Implementation has addressed several issues relevant to creation of a large scale post-marketing drug safety surveillance system envisioned by the FDA's Sentinel Initiative... - Potential population-based electronic data sources for rapid pandemic influenza vaccine adverse event detection: a survey of health plansKristen M Moore
Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
Pharmacoepidemiol Drug Saf 17:1137-41. 2008..Many public and private health plans and payers have such information... - Impact of exposure accrual on sequential postmarket evaluations: a simulation studyJudith C Maro
Engineering Systems Division, Massachusetts Institute of Technology, Cambridge, MA, USA
Pharmacoepidemiol Drug Saf 20:1184-91. 2011..We discuss the role of SDS analyses in the US Food and Drug Administration's planned Sentinel System and suggest the outline of a decision-analytic framework that might aid regulatory authorities in planning postmarket surveillance... - The U.S. Food and Drug Administration's Mini-Sentinel program: status and directionRichard Platt
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
Pharmacoepidemiol Drug Saf 21:1-8. 2012.... - Real-time vaccine safety surveillance for the early detection of adverse eventsTracy A Lieu
Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Massachusetts, USA
Med Care 45:S89-95. 2007..Sequential testing procedures are needed to detect vaccine or drug safety problems as soon as possible after introduction... - Risk of Guillain-Barré syndrome after meningococcal conjugate vaccinationPriscilla Velentgas
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
Pharmacoepidemiol Drug Saf 21:1350-8. 2012..We conducted a study to assess the risk of GBS after MCV4 vaccination using health plan administrative and claims data together with the review of primary medical records of potential cases... 
Near real-time adverse drug reaction surveillance within population-based health networks: methodology considerations for data accrualTaliser R Avery
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA The HMO Research Network Center for Education and Research in Therapeutics, Boston, MA, USA
Pharmacoepidemiol Drug Saf 22:488-95. 2013..This study describes practical considerations for implementation of near real-time medical product safety surveillance in a distributed health data network...- A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid populationDennis Ross-Degnan
Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
Int J Psychiatry Med 34:103-23. 2004..CONCLUSIONS: State-mandated physician surveillance dramatically reduces BZ use with limited substitution of alternative drugs, lowers rates of possible abuse, but may severely limit non-problematic BZ use... - Effect of the Heart At Work program on awareness of risk factors, self-efficacy, and health behaviorsCheryl Pegus
Pfizer, Inc, New York, N.Y, USA
J Occup Environ Med 44:228-36. 2002..They also were more likely to begin treatment for hypertension, to report fewer sick days, and to have plans to improve their diet and lose weight. These findings suggest that the Heart At Work program had a favorable overall impact...